Hikma Pharmaceuticals Plc Director/PDMR Shareholding (8914Y)
March 08 2017 - 8:30AM
UK Regulatory
TIDMHIK
RNS Number : 8914Y
Hikma Pharmaceuticals Plc
08 March 2017
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
The attached individual notification made under article 19.1 of
the Market Abuse Regulation ("MAR") relates to the pledge by
Darhold Limited of Ordinary Shares of 10 pence each in Hikma
Pharmaceuticals PLC. The Chairman and Chief Executive, Vice
Chairman and a Non-Executive Director are directors of and
shareholders in Darhold Limited. This announcement is made in
accordance with article 19.3 of MAR.
Said Darwazah
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Said Darwazah
--- --------------------- ----------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Chairman and Chief Executive Officer
/ PDMR
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ----------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 6,500,000 to 9,750,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of J. Safra Sarasin Limited. The
Chairman and Chief Executive is a
director of and shareholder in Darhold
Limited with an equity interest of
21.49%.
--- --------------------- ----------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 3,250,000
--- --------------------- ----------------------------------------
d) Aggregated Aggregated volume: 3,250,000
information Price: GBP0.00p
--- --------------------- ----------------------------------------
e) Date of the 6 March 2017
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ----------------------------------------
Mazen Darwazah
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Mazen Darwazah
--- --------------------- ----------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Executive Vice Chairman / PDMR
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ----------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 6,500,000 to 9,750,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of J. Safra Sarasin Limited. The
Executive Vice Chairman is a director
of and shareholder in Darhold Limited
with an equity interest of 10.82%.
--- --------------------- ----------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 3,250,000
--- --------------------- ----------------------------------------
d) Aggregated Aggregated volume: 3,250,000
information Price: GBP0.00p
--- --------------------- ----------------------------------------
e) Date of the 6 March 2017
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ----------------------------------------
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Mohammed 'Ali' Al-Husry
--- --------------------- ----------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Non-Executive Director/ PDMR
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ----------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 6,500,000 to 9,750,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of J. Safra Sarasin Limited. The
Non-Executive Director is a director
of and shareholder in Darhold Limited
with an equity interest of 7.95%.
--- --------------------- ----------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 3,250,000
--- --------------------- ----------------------------------------
d) Aggregated Aggregated volume: 3,250,000
information Price: GBP0.00p
--- --------------------- ----------------------------------------
e) Date of the 6 March 2017
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ----------------------------------------
Peter Speirs, Company Secretary, Responsible for releasing this
announcement
8 March 2017
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBXGDXCDGBGRI
(END) Dow Jones Newswires
March 08, 2017 08:30 ET (13:30 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Aug 2023 to Aug 2024